Cipla enters joint venture with Cooper Pharma and the Pharmaceutical Institute in Morocco

Published: 10-Feb-2015
Finance

Cipla (EU) Limited will focus on respiratory and neurology portfolio and set up manufacturing plant in the country


Indian pharmaceutical company Cipla has formed a joint venture (JV) agreement with Morocco-based Societe Marocaine De Cooperation Pharmaceutique (Cooper Pharma) and the Pharmaceutical Institute (PHI) to enhance its presence in the region.

Cipla (EU) Limited, a wholly owned subsidiary of the Mumbai-based firm, has signed the JV with the Moroccan companies.

The JV will initially focus on respiratory and neurology products and will also invest in setting up a manufacturing facility in Morocco, the company said.

Cipla (EU) Limited will hold a 60% stake in the JV, while Cooper Pharma and PHI shall together hold 40%. Cipla (EU) Limited will invest up to US$15m in the JV.

Subhanu Saxena, Cipla's MD and Global CEO, said: 'Morocco is an attractive pharmaceutical market in the African continent. This JV is aimed to strengthen Cipla’s presence in Morocco, which is in-line with our global growth strategy to build front-end presence in key markets. Cipla has enjoyed a long-standing business relationship with Cooper Pharma and PHI for over a decade and this JV will further strengthen Cipla’s relationship.'

  • Companies:
  • Cipla
See more

You may also like

Finance

Cipla and Kemwell announce joint venture for biosimilars

Read more
The venture will leverage the companies’ combined strengths in product development, clinical development, regulatory filings, manufacturing and commercialisation

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Finance

Cipla and Kemwell announce joint venture for biosimilars

The venture will leverage the companies’ combined strengths in product development, clinical development, regulatory filings, manufacturing and commercialisation
Ingredients

Cipla signs COVID-19 licensing agreement with Gilead Sciences

Indian Cipla will be permitted to manufacture US-based Gilead’s API and finished product of Remdesivir and market it in 127 countries including India and South Africa under its own brand name
Research & Development

Indian Cipla funnels $1 million into facility in Minsk

The facility will be used to localise the production of innovative solid medicines in Belarus
Finance

Cipla to step up efforts in US market

Competition heating up, with the US Food and Drug Association approving rival drugs, which could eat away at Cipla's market share in the generic business.
Finance

Cipla to acquire two US generics companies for $550m

Acquisition of InvaGen gives Cipla scale in the US generics market with a strong manufacturing and R&D base, access to a broad product portfolio and a strong customer base
Finance

Operating margins expected to grow by 28% year-on-year for Indian pharma firms

Most are focusing on niche products in the US
Finance

Indian drug companies expected to sustain margin improvement

India business is bouncing back aided by favourable exchange rates
Subscribe now